Search

Your search keyword '"La Sala, Antonio"' showing total 76 results
Start Over Author "La Sala, Antonio"
76 results on '"La Sala, Antonio"'

51. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

Author

Dell'olio, Matteo, primary, Potito scalzulli, Rosario, additional, Sanpaolo, Grazia, additional, Nobile, Michele, additional, Saverio mantuano, Francesco, additional, La sala, Antonio, additional, D'arena, Giovanni, additional, Miraglia, Eustachio, additional, Lucania, Anna, additional, Mastrullo, Lucia, additional, and Nicola, Cascavilla, additional

Published
2011
Full Text
View/download PDF

52. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

Author

Federico, Massimo, primary, Luminari, Stefano, additional, Iannitto, Emilio, additional, Polimeno, Giuseppe, additional, Marcheselli, Luigi, additional, Montanini, Antonella, additional, La Sala, Antonio, additional, Merli, Francesco, additional, Stelitano, Caterina, additional, Pozzi, Samantha, additional, Scalone, Renato, additional, Di Renzo, Nicola, additional, Musto, Pellegrino, additional, Baldini, Luca, additional, Cervetti, Giulia, additional, Angrilli, Francesco, additional, Mazza, Patrizio, additional, Brugiatelli, Maura, additional, and Gobbi, Paolo G., additional

Published
2009
Full Text
View/download PDF

54. Safety and Efficacy of Laparoscopic Splenectomy in Patients with Refractory Immune Thrombocytopenic Purpura. A Long-Term Survey

Author

Cascavilla, Nicola, primary, Scaramuzzi, Matteo, primary, Nobile, Michele, primary, Dell’Olio, Matteo, primary, Falcone, Antonietta Pia, primary, Melillo, Lorella, primary, Sanpaolo, Grazia, primary, Scalzulli, Potito Rosario, primary, Rossi, Giovanni, primary, La Sala, Antonio, primary, Bodenizza, Carlo, primary, D’Arena, Giovanni, primary, Mantuano, Francesco Saverio, primary, Greco, Michele Mario, primary, Carella, Angelo Michele, primary, Merla, Emanuela, primary, Ambrosio, Angelo, primary, and Di Sebastiano, Pierluigi, primary

Published
2008
Full Text
View/download PDF

56. Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Author

Scalzulli, Potito Rosario, primary, Valvano, Maria Rosa, additional, Bodenizza, Carlo C., additional, Carella, Angelo Michele, additional, Dell’Olio, Matteo M., additional, Falcone, Antonietta A.P., additional, Greco, Michele Mario, additional, La Sala, Antonio A., additional, Mantuano, Francesco F.S., additional, Melillo, Lorella L., additional, Merla, Emanuela E., additional, Nobile, Michele M., additional, Sanpaolo, Sanpaolo G., additional, and Cascavilla, Nicola N., additional

Published
2007
Full Text
View/download PDF

57. Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).

Author

Cascavilla, Nicola, primary, Bodenizza, Carlo, additional, Carella, Angelo Michele, additional, Dell’Olio, Matteo, additional, Falcone, Antonietta Pia, additional, Greco, Michele Mario, additional, La Sala, Antonio, additional, Mantuano, Saverio, additional, Melillo, Lorella, additional, Merla, Emanuela, additional, Nobile, Michele, additional, Sanpaolo, Grazia, additional, and Scalzulli, Potito, additional

Published
2007
Full Text
View/download PDF

58. Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.

Author

Cascavilla, Nicola, primary, Bodenizza, Carlo, primary, Carella, Angelo Michele, primary, Dell’Olio, Matteo, primary, Falcone, Antonietta, primary, Greco, Michele Mario, primary, La Sala, Antonio, primary, Mantuano, Saverio, primary, Melillo, Lorella, primary, Merla, Emanuela, primary, Nobile, Michele, primary, Sanpaolo, Grazia, primary, and Scalzulli, Potito, primary

Published
2006
Full Text
View/download PDF

59. MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors

Author

Gobbi, Paolo G., primary, Broglia, Chiara, additional, Levis, Alessandro, additional, La Sala, Antonio, additional, Valentino, Francesco, additional, Chisesi, Teodoro, additional, Sacchi, Stefano, additional, Corbella, Franco, additional, Cavanna, Luigi, additional, Iannitto, Emilio, additional, Pavone, Vincenzo, additional, Molica, Stefano, additional, Corazza, Gino Roberto, additional, and Federico, Massimo, additional

Published
2006
Full Text
View/download PDF

63. Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.

Author

Musto, Pellegrino, primary, Rosario Scalzulli, Potito, additional, Melillo, Lorella, additional, Nobile, Michele, additional, Dell’Olio, Matteo, additional, La Sala, Antonio, additional, Mantuano, Saverio, additional, Bodenizza, Carlo, additional, Falcone, Antonietta, additional, Sanpaolo, Grazia, additional, Michele Carella, Angelo, additional, Greco, Michele Mario, additional, Beltrami, Germana, additional, and Cascavilla, Nicola, additional

Published
2004
Full Text
View/download PDF

64. Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis

Author

Musto, Pellegrino, primary, Falcone, Antonietta, additional, Sanpaolo, Grazia, additional, Bodenizza, Carlo, additional, Perla, Gianni, additional, Minervini, Maria Marta, additional, Cascavilla, Nicola, additional, Dell'olio, Matteo, additional, La Sala, Antonio, additional, Mantuano, Saverio, additional, Melillo, Lorella, additional, Nobile, Michele, additional, Scalzulli, Potito Rosario, additional, Bisceglia, Michele, additional, and Carella, Angelo Michele, additional

Published
2004
Full Text
View/download PDF

65. Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial

Author

Michele Carella, Angelo, primary, Musto, Pellegrino, additional, Falcone, Antonietta, additional, Sanpaolo, Grazia, additional, Bodenizza, Carlo, additional, Cascavilla, Nicola, additional, Melillo, Lorella, additional, Rosario Scalzulli, Potito, additional, Dell'Olio, Matteo, additional, La Sala, Antonio, additional, Mantuano, Saverio, additional, and Nobile, Michele, additional

Published
2003
Full Text
View/download PDF

66. Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial

Author

Musto, Pellegrino, primary, Falcone, Antonietta, additional, Sanpaolo, Grazia, additional, Bodenizza, Carlo, additional, Cascavilla, Nicola, additional, Melillo, Lorella, additional, Calzulli, Potito Rosario, additional, Del l'olio, Matteo, additional, La Sala, Antonio, additional, Mantuano, Saverio, additional, Nobile, Michele, additional, and Carella, Angelo Michele, additional

Published
2003
Full Text
View/download PDF

67. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

Author

D'Arena, Giovanni, Laurenti, Luca, Coscia, Marta, Cortelezzi, Agostino, Chiarenza, Annalisa, Pozzato, Gabriele, Vigliotti, Maria Luigia, Nunziata, Giuseppe, Fragasso, Alberto, Villa, Maria Rosaria, Grossi, Alberto, Selleri, Carmine, Deaglio, Silvia, La Sala, Antonio, Del Poeta, Giovanni, Simeon, Vittorio, Aliberti, Luig, De Martino, Laura, Giudice, Aldo, and Musto, Pellegrino

Subjects
CHRONIC lymphocytic leukemia treatment, RESEARCH in alternative medicine, NATUROPATHY, CANCER patients, DIET in disease, CANCER & nutrition
Abstract

Complementary and alternative medicine (CAM) is common in patients with cancer and its use is steadily increasing over time. We performed a multicenter survey in which the use of CAM in 442 Italian patients with chronic lymphocytic leukemia (CLL), the commonest form of leukemia in Western countries, was assessed. Data were collected by means of a face-to-face standardized questionnaire with several items. Mean age was 69 years; 258 patients (58%) were male and 184 (42%) female. Seventy-three patients (16.5%) were found to be CAM users. The most common CAM therapies were green tea, aloe formulations and high dose vitamins. Predictors of CAM use were female gender, younger age, higher education level, internet availability and newspaper reading. The reasons for CAM popularity among these patients are complex. Given the number of patients combining therapy with CAM and its possible drug interactions, doctor interest as well as patient education about CAM should be improved. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

69. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.

Author

D'Arena, Giovanni, Vigliotti, Maria Luigia, Dell'Olio, Matteo, Villa, Maria Rosaria, Mantuano, Saverio, Scalzulli, Potito Rosario, La Sala, Antonio, Abbadessa, Antonio, Mastrullo, Lucia, and Cascavilla, Nicola

Subjects
ERYTHROCYTE disorders, LYMPHOPROLIFERATIVE disorders, APLASTIC anemia, LYMPHATIC diseases, THERAPEUTICS
Abstract

We report four patients (mean age 65 yr; range 40–77 yr) affected by acquired pure red cell aplasia (PRCA) complicating chronic lymphoid disorders and treated with anti-CD20 monoclonal antibody rituximab. Three out of four patients were given packed red cell transfusion. Steroids and recombinant erythropoietin (r-Epo) were also administered as first-line therapy without response. After a mean time of 57 d (range 23–62 d) from PRCA diagnosis, all patients received rituximab at a dosage of 375 mg/m2/wk for four consecutive weeks. First injection side effects of rituximab were minimal. All patients showed an increase in hemoglobin levels in response to rituximab, in one patient just after the first dose, in another patient after the second and in two other patients after the third dose. Three patients (75%) were considered in complete remission (CR) and one patient (25%) in partial remission 4 wk after the last rituximab infusion, despite a CR was obtained later (16 wk following the beginning of the therapy). Finally, at the last follow-up (mean 18.5 months, range 2–60 months), all patients were alive and in continue CR. Despite very limited in number, these results suggest that rituximab is very effective in the treatment of PRCA complicating B-cell chronic lymphoproliferative disorders. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

72. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.

Author

Vigliotti, Maria Luigia, Dell’Olio, Matteo, La Sala, Antonio, Romano, Giampiero, Tartarone, Alfredo, Mele, Giuseppe, Musto, Clelia, Carella, Angelo Michele, and Di Renzo, Nicola

Subjects
*LYMPHOMAS, *CANCER, *DRUG therapy, *PROGNOSIS, *MEDICAL research, CENTRAL nervous system tumors
Abstract

Discusses the prognosis and treatment for primary central nervous system lymphoma (PCNSL) in immunocompetent adults. Combination of chemotherapy and radiotherapy for PCNSL; Review on the pharmacodynamic properties and therapeutic potential in the chemotherapy of lymphomas; Need for an optimal treatment of patients with PCNSL.

Published
2004
Full Text
View/download PDF

73. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey

Author

D'Arena, G, Laurenti, L, Coscia, Cortelezzi, M, A, Chiarenza, A, Pozzato, G, Vigliotti, M, Nunziata, G, Fragasso, A, Villa, M, Grossi, A, Selleri, C, Deaglio, S, La Sala, A, DEL POETA, G, Simeon, V, Aliberti, L, De Martino, L, Giudice, A, Musto, P, De Feo, V, D'Arena, Giovanni, Laurenti, Luca, Coscia, Marta, Cortelezzi, Agostino, Chiarenza, Annalisa, Pozzato, Gabriele, Vigliotti, Maria Luigia, Nunziata, Giuseppe, Fragasso, Alberto, Villa, Maria Rosaria, Grossi, Alberto, Selleri, Carmine, Deaglio, Silvia, La Sala, Antonio, Del Poeta, Giovanni, Simeon, Vittorio, Aliberti, Luig, De Martino, Laura, Giudice, Aldo, Musto, Pellegrino, and De Feo, Vincenzo

Subjects
Adult, Complementary Therapies, Male, Cancer Research, medicine.medical_specialty, animal structures, Younger age, Chronic lymphocytic leukemia, Alternative medicine, MEDLINE, chronic lymphocytic leumia, therapy, Risk Factors, Internal medicine, Surveys and Questionnaires, Medicine, Humans, In patient, Aged, Neoplasm Staging, Aged, 80 and over, Geography, business.industry, leukemic progenitor cell, Cancer, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Oncology, Italy, Health Care Surveys, Immunology, erythrocytes, Female, Lymphocyte, business, Settore MED/15 - Malattie del Sangue, CLL, Patient education
Abstract

Complementary and alternative medicine (CAM) is common in patients with cancer and its use is steadily increasing over time. We performed a multicenter survey in which the use of CAM in 442 Italian patients with chronic lymphocytic leukemia (CLL), the commonest form of leukemia in Western countries, was assessed. Data were collected by means of a face-to-face standardized questionnaire with several items. Mean age was 69 years; 258 patients (58%) were male and 184 (42%) female. Seventy-three patients (16.5%) were found to be CAM users. The most common CAM therapies were green tea, aloe formulations and high dose vitamins. Predictors of CAM use were female gender, younger age, higher education level, internet availability and newspaper reading. The reasons for CAM popularity among these patients are complex. Given the number of patients combining therapy with CAM and its possible drug interactions, doctor interest as well as patient education about CAM should be improved.

Published
2014

74. Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.

Author

Morabito F, Hohaus S, Mammi C, Marcheselli L, Gentile M, Merli F, Montanini A, Stelitano C, La Sala A, Scalone R, Voso MT, Luminari S, Iannitto E, Gobbi P, and Federico M

Subjects
Adult, Anemia chemically induced, Anemia genetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biotransformation genetics, Bleomycin administration & dosage, Bleomycin adverse effects, Bleomycin pharmacokinetics, Carboplatin administration & dosage, Carboplatin adverse effects, Carboplatin pharmacokinetics, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Cyclophosphamide pharmacokinetics, Dacarbazine administration & dosage, Dacarbazine adverse effects, Dacarbazine pharmacokinetics, Doxorubicin administration & dosage, Doxorubicin adverse effects, Doxorubicin pharmacokinetics, Epirubicin administration & dosage, Epirubicin adverse effects, Epirubicin pharmacokinetics, Etoposide administration & dosage, Etoposide adverse effects, Etoposide pharmacokinetics, Female, Gene Deletion, Genetic Predisposition to Disease, Genotype, Glutathione S-Transferase pi physiology, Glutathione Transferase physiology, Hodgkin Disease drug therapy, Hodgkin Disease genetics, Hodgkin Disease mortality, Humans, Lomustine administration & dosage, Lomustine adverse effects, Lomustine pharmacokinetics, Male, Middle Aged, Neoplasm Proteins physiology, Polymorphism, Single Nucleotide, Prednisone administration & dosage, Prednisone adverse effects, Prednisone pharmacokinetics, Procarbazine administration & dosage, Procarbazine adverse effects, Procarbazine pharmacokinetics, Prognosis, Treatment Outcome, Vinblastine administration & dosage, Vinblastine adverse effects, Vinblastine pharmacokinetics, Vincristine administration & dosage, Vincristine adverse effects, Vincristine pharmacokinetics, Vindesine administration & dosage, Vindesine adverse effects, Vindesine pharmacokinetics, Glutathione S-Transferase pi genetics, Glutathione Transferase genetics, Hodgkin Disease enzymology, Neoplasm Proteins genetics, Polymorphism, Genetic
Abstract

Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95% C.I., 1.16-21.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95% C.I. 1.28- 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen.

Published
2012
Full Text
View/download PDF

75. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.

Author

Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, and Palumbo A

Subjects
Adult, Aged, Angiogenesis Inhibitors administration & dosage, Antineoplastic Agents adverse effects, Boronic Acids adverse effects, Bortezomib, Female, Humans, Leukopenia etiology, Male, Middle Aged, Multiple Myeloma complications, Multiple Myeloma mortality, Pyrazines adverse effects, Recurrence, Thalidomide administration & dosage, Thrombocytopenia etiology, Transplantation, Homologous, Antineoplastic Agents administration & dosage, Boronic Acids administration & dosage, Multiple Myeloma therapy, Pyrazines administration & dosage, Salvage Therapy, Stem Cell Transplantation
Abstract

Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib (1.3 mg/m(2) body surface twice weekly for 2 weeks followed by an interval of 10-12 days) without adjunct of steroids as third line therapy. Three patients died of progressive disease during the first 2 cycles with bortezomib. Eighteen patients received at least 2 cycles and were evaluated for response. According to EBMT criteria, two complete (negative immunofixation) and seven partial (reduction of M-component > 50-75%) remissions were achieved (ITT response rate 42.8%). Duration of response lasted from 2 to 14+ months. Grades 3-4 toxicities (thrombocytopenia, leucopenia, peripheral neuropathy and vasculitis) were observed in seven patients, but no patient interrupted the treatment due to side effects. We conclude that bortezomib alone may induce high quality responses as third line salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated myeloma patients with progressive disease after autologous transplantation and thalidomide.

Published
2006
Full Text
View/download PDF

76. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.

Author

Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, and Carella AM

Subjects
Aged, Anemia blood, Anemia etiology, Darbepoetin alfa, Erythrocyte Count, Erythropoietin blood, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Myelodysplastic Syndromes blood, Myelodysplastic Syndromes complications, Pilot Projects, Anemia drug therapy, Erythropoietin analogs & derivatives, Erythropoietin therapeutic use, Myelodysplastic Syndromes drug therapy
Abstract

Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 microg s.c. for at least 12 weeks. Fifteen patients (40.5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin <100 IU/l, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results